



Vivimed

Dated : November 12,2012

To
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

Dear Sir/Madam,

Subject : Outcome of Board Meeting


Ref: Clause 41 of Listing Agreement

With reference to captioned subject and pursuant to clause 41 of Listing Agreement entered into with the stock Exchange, we are hereby submitting Unaudited financial results for the Quarter ended on September 30,2012 approved by the Board of Directors at their meeting held on November 12,2012.

This is for your information and record.

Thanking You,

For VIVIMED LABS LIMITED


SANTOSH VARALWAR

MANAGING DIRECTOR & CEO

VIVIMED LABS LIMITED
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30th, 2012

INR In Lacs

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Ended
		30.09.2012 (Unaudited)	30.06.2012 (Unaudited)	30.09.2011 (Unaudited)	30.09.2012 (Unaudited)	30.09.2011 (Unaudited)	31.03.2012 (Audited)
1	Income From Operations						
*	(a) Net Sales / Income from Operations (Net of Excise Duty)	10,958.42	9,116.06	9,510.82	20,074.48	19,903.78	38,289.99
	(b) Other Operating Income	155.57	38.93	14.53	194.50	16.53	41.96
	Total Income From Operations (Net)	11,113.99	9,154.99	9,525.35	20,268.98	19,920.32	38,331.95
2	Expenses	8,977.86	7,204.08	7,654.88	16,181.94	16,112.82	30,944.43
	a. Cost of Raw Materials Consumed	6,047.12	6,475.81	6,489.64	12,522.93	12,596.45	22,930.02
	b. Purchase of Stock in Trade	-	-	-	-	-	-
	Trade	644.46	(2,028.62)	(563.05)	(1,384.16)	(629.09)	(156.78)
	d. Employee Benefit Expenses	414.23	341.75	246.13	755.97	534.31	1,057.86
	e. Depreciation and Amortisation Expenses	380.30	372.43	247.90	752.73	389.12	1,055.10
	f. Other Expenditure	1,491.75	2,042.71	1,234.27	3,534.46	3,222.03	6,058.23
	Total Expenses	8,977.86	7,204.08	7,654.88	16,181.94	16,112.82	30,944.43
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	2,136.13	1,950.91	1,870.47	4,087.04	3,807.50	7,387.52
4	Other Income	-	-	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	2,136.13	1,950.91	1,870.47	4,087.04	3,807.50	7,387.52
6	Finance Costs	680.81	895.01	696.83	1,575.82	1,283.38	2,253.49
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,455.32	1,055.90	1,173.64	2,511.22	2,524.12	5,134.02
8	Exceptional items	-	-	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	1,455.32	1,055.90	1,173.64	2,511.22	2,524.12	5,134.02
10	Tax Expenses	537.95	211.18	234.82	749.13	505.02	1,092.57
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	917.37	844.72	938.82	1,762.09	2,019.10	4,041.46
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	917.37	844.72	938.82	1,762.09	2,019.10	4,041.46
14	Share of Profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	917.37	844.72	938.82	1,762.09	2,019.10	4,041.46
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1393.39	1393.39	1,244.39	1,393.39	1,244.39	1,393.39
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-	25,672.32
19	Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)	-	-	-	-	-	-
	(a) Basic	6.58	6.06	7.54	12.65	16.23	29.00
	(b) Diluted	5.71	5.26	7.46	10.97	14.49	25.16



1. The above Standalone Unaudited Financial Results for the Quarter ended September 30, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on November 12, 2012.
2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

Place : Hyderabad

Date : 12/11/2012

For VIVIMED LABS LIMITED


(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED - STANDALONE
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING
OF THE LISTING AGREEMENT

(INR in Lacs)

Particulars	3 Months ended		6 Months Ended		Year Ended
	Unaudited		Unaudited		Audited
	30-09-2012	30-09-2011	30-09-2012	30-09-2011	31-03-2012
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	8,582.74	6,874.02	15,430.76	14,518.14	27,873.35
b.Pharma Business	2,375.68	2,636.80	4,643.72	5,385.64	10,416.65
Total	10,958.42	9,510.82	20,074.48	19,903.78	38,289.99
Less, Inter Segment Revenue	-	-	-	-	-
Net sales / Income from Operations	10,958.42	9,510.82	20,074.48	19,903.78	38,289.99
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment					
a.Speciality Chemicals Business	1,799.35	1,228.68	3,323.96	2,603.01	4,970.17
b.Pharma Business	336.78	641.79	763.09	1,204.49	2,417.35
Total	2,136.13	1,870.47	4,087.04	3,807.50	7,387.52
Less: 1. Interest	680.81	696.83	1,575.82	1,283.38	2,253.49
2. Other Un-allocable Expenditure	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
Total Profit Before Tax	1,455.32	1,173.64	2,511.22	2,524.12	5,134.03
3. Capital Employed					
a.Speciality Chemicals Business	78,359.87	55,931.79	78,359.87	55,931.79	64,436.00
b.Pharma Business	7,380.55	5,232.27	7,380.55	5,232.27	6,003.20
Total	85,740.42	61,164.06	85,740.42	61,164.06	70,439.20

Place : Hyderabad
Date : 12/11/2012

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



Vivimed Labs Limited

Statement of Assets & Liabilities as at 30.09.2012 - STANDALONE

(INR in Lacs)

S.No	Particulars	As at	As at
		30.09.2012 UnAudited	31.03.2012 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	(a) Share Capital		
	Equity Share Capital	1,393.39	1,393.39
	Preference Share capital	6,700.00	6,700.00
	(b) Reserves and Surplus	26,644.04	26,201.50
	(c) Money Received against Share Warrants	237.21	237.21
	Sub Total Shareholders Funds	34,974.64	34,532.10
2	Share application money pending allotment	-	-
3	Minority interest *		
4	Non-current liabilities		
	a) Long-term borrowings	21,034.48	13,999.70
	(b) Deferred tax liabilities (net)	1,881.17	1,634.30
	(c) Other long-term liabilities	3,224.88	473.63
	(d) Long-term provisions	116.19	180.90
	Sub-total - Non-current liabilities	26,256.72	16,288.53
5	Current liabilities		
	(a) Short-term borrowings	24,955.87	20,255.36
	(b) Trade payables	8,948.71	2,772.42
	(c) Other current liabilities	587.65	2,715.60
	(d) Short-term provisions	1,487.32	1,184.41
	Sub-total - Current liabilities	35,979.55	26,927.79
	TOTAL - EQUITY AND LIABILITIES	97,210.91	77,748.43
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	38,936.58	29,449.48
	(b) Capital Work In Progress	1,451.61	770.83
	(b) Goodwill on Consolidation*	-	-
	(c) Non Current Investment	8,716.93	8,716.93
	(d) Deferred Tax Assets (net)	-	-
	(e) Long Term Loans and advances	-	-
	(f) Other Non Current Assets	6.46	3,006.13
	Sub-total - Non-current assets	49,111.58	41,943.37
2	Current Assets		
	(b) Inventories	10,488.58	7,388.21
	(c) Trade receivables	14,565.86	9,871.75
	(d) Cash and cash equivalents	1,725.27	1,940.55
	(e) Short-term loans and advances	21,319.61	16,581.59
	(f) Other current assets	-	22.95
	Sub-total - Current assets	48,099.33	35,805.05
	TOTAL - ASSETS	97,210.91	77,748.43



Handwritten signature

VIVIMED LABS LIMITED							
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED September 30th, 2012							
INR In Lacs							
		<i>Quarter Ended</i>			<i>Half Year Ended</i>		<i>Previous Year Ended</i>
Sl. No.	Particulars	30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012
		<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Audited)</i>
1	Income From Operations						
	<i>(a) Net Sales / Income from Operations (Net of Excise Duty)</i>	26,608.92	27,251.66	12,870.18	53,860.58	24,924.30	66,831.38
	<i>(b) Other Operating Income</i>	973.71	180.85	11.48	1,154.56	19.79	268.23
	Total Income From Operations (Net)	27,582.63	27,432.52	12,881.66	55,015.14	24,944.09	67,099.61
2	Expenses	23,600.44	22,651.54	10,469.64	46,251.99	20,325.74	56,480.55
	<i>a. Cost of Raw Materials Consumed</i>	12,497.70	13,969.45	8,070.47	26,467.15	15,089.64	35,573.68
	<i>b. Purchase of Stock in Trade</i>	-	-	-	-	-	-
	<i>c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade</i>	523.15	(2,974.65)	(657.47)	(2,451.50)	(1,319.81)	(1,835.31)
	<i>d. Employee Benefit Expenses</i>	1,240.34	1,424.33	712.55	2,664.68	1,199.00	3,422.45
	<i>e. Depreciation and Amortisation Expenses</i>	1,406.79	1,413.00	378.56	2,819.79	643.17	2,678.94
	<i>f. Other Expenditure</i>	7,932.45	8,819.42	1,965.52	16,751.87	4,713.74	16,640.79
	Total Expenses	23,600.44	22,651.54	10,469.64	46,251.99	20,325.74	56,480.55

3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	3,982.18	4,780.97	2,412.02	8,763.16	4,618.35	10,619.06
4	Other Income	-	-	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	3,982.18	4,780.97	2,412.02	8,763.16	4,618.35	10,619.06
6	Finance Costs	1,075.40	1,589.06	791.14	2,664.45	1,441.79	2,837.54
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	2,906.78	3,191.92	1,620.88	6,098.70	3,176.56	7,781.52
8	Exceptional items	-	-	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	2,906.78	3,191.92	1,620.88	6,098.70	3,176.56	7,781.52
10	Tax Expenses	353.09	578.94	378.82	932.03	695.24	1,467.84
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,553.70	2,612.98	1,242.06	5,166.67	2,481.32	6,313.68
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	2,553.70	2,612.98	1,242.06	5,166.67	2,481.32	6,313.68
14	Share of Profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,553.70	2,612.98	1,242.06	5,166.67	2,481.32	6,313.68
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,393.39	1,393.39	1,244.39	1,393.39	1,244.39	1,393.39
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-	-

19	Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)	-	-	-			-
	(a) Basic	18.33	18.75	9.98	37.08	19.94	45.31
	(b) Diluted	15.90	16.26	9.86	32.17	17.81	39.31

1. The above Consolidated Unaudited Financial Results for the Quarter ended September 30, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on November 12, 2012.
2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octtantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited (vi) Vivimed Labs Mauritius Limited and its step down subsidiaries viz. (i) Vivimed Labs Europe Limited (ii) Vivimed Labs UK Limited, (iii) Vivimed Labs Spain, S.L. (iv) Union Quimico Farmaceutica S.A.U., Spain, (v) Uquifa Mexico S.A. de C.V. & (vi) Hoiliday International Limited, UK.
3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED



**(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO**




Place : Hyderabad

Date : 12/11/2012

VIVIMED LABS LIMITED - CONSOLIDATED					
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE					
LISTING AGREEMENT					
					<i>(INR in Lacs)</i>
Particulars	3 Months ended		6 Months Ended		12 Months ended
	Unaudited		Unaudited		Audited
	30-09-2012	30-09-2011	30-09-2012	30-09-2011	31-03-2012
1. Segment Revenue					
<i>(Net Sales/Income from each segment should be disclosed under this head)</i>					
<i>a. Speciality Chemicals Business</i>	11,935.17	10,861.40	22,451.84	21,113.20	33,626.26
<i>b. Pharma Business</i>	17,576.75	4,009.90	36,660.84	7,788.40	33,205.12
Total	29,511.92	14,871.30	59,112.68	28,901.60	66,831.38
<i>Less : Inter Segment Revenue</i>	2,903.00	2,001.10	5,252.09	3,977.30	
Net sales / Income from Operations	26,608.92	12,870.20	53,860.58	24,924.30	66,831.38
2.Segment Results(Profit)(+)/Loss(-)					
<i>before tax and interest from each segment</i>					
<i>a.Speciality Chemicals Business</i>	1,896.46	1,622.82	3,866.25	3,127.00	6,006.97
<i>b.Pharma Business</i>	2,085.72	789.14	4,896.91	1,491.30	4,612.10
Total	3,982.18	2,411.97	8,763.16	4,618.30	10,619.06
<i>Less: 1.Interest</i>				1,441.80	2,837.54

	1,075.40	791.10	2,664.45		
2. Other Un-allocable Expenditure net off	-	-	-	-	-
3. Un-allocable Income	-	-			-
Total Profit Before Tax	2,906.78	1,620.87	6,098.70	3,176.50	7,781.52
3. Capital Employed					
a. Speciality Chemicals Business	81,276.11	71,794.00	81,276.11	71,794.00	68,235.00
b. Pharma Business	45,784.65	9,402.10	45,784.65	9,402.10	40,330.20
Total	1,27,060.76	81,196.10	1,27,060.76	81,196.10	1,08,565.20

For VIVIMED LABS LIMITED




Place : Hyderabad
Date : 12/11/2012

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO

Vivimed Labs Limited

Statement of Assets & Liabilities as at 30.09.2012 - CONSOLIDATED

(INR in Lacs)

S.No	Statement of Assets and Liabilities Particulars	As at	As at
		30.09.2012 Unaudited	31.03.2012 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	(a) Share Capital	-	-
	Equity Share Capital	1,393.39	1,393.39
	Preference Share capital	13,094.56	13,094.56
	(b) Reserves and Surplus	33,527.02	32,753.20
	(c) Money Received against Share Warrants	237.21	237.20
	Sub Total Shareholders Funds	48,252.18	47,478.36
2	Share application money pending allotment	-	-
3	Minority interest *		
4	Non-current liabilities		
	a) Long-term borrowings	41,562.91	33,732.53
	(b) Deferred tax liabilities (net)	1,092.40	1,344.05
	(c) Other long-term liabilities	3,233.88	175.52
	(d) Long-term provisions	116.19	180.90
	Sub-total - Non-current liabilities	46,005.39	35,433.00
5	Current liabilities		
	(a) Short-term borrowings	28,984.08	23,282.27
	(b) Trade payables	20,379.61	15,686.35
	(c) Other current liabilities	3,418.15	4,719.17
	(d) Short-term provisions	3,442.58	3,321.15
	Sub-total - Current liabilities	56,224.41	47,008.95
	TOTAL - EQUITY AND LIABILITIES	1,50,481.98	1,29,920.30
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	67,281.42	59,534.44
	(b) Capital Work In Progress	2,956.29	836.81
	(b) Goodwill on Consolidation*	-	-
	(c) Non Current Investment	51.94	69.80
	(d) Deferred Tax Assets (net)	-	-
	(e) Long Term Loans and advances	-	-
	(f) Other Non Current Assets	1,982.78	4,765.49
	Sub-total - Non-current assets	72,272.43	65,206.55
2	Current Assets		
	(a) Current investments	-	-
	(b) Inventories	30,994.95	24,787.74
	(c) Trade receivables	26,734.10	22,160.78
	(d) Cash and cash equivalents	3,177.15	3,633.68
	(e) Short-term loans and advances	16,723.60	14,108.56
	(f) Other current assets	579.76	22.99
	Sub-total - Current assets	78,209.55	64,713.75
	TOTAL - ASSETS	1,50,481.98	1,29,920.30



Part II					
Select Information for the Quarter Ended 30/09/2012					
	Particulars	3 months ended 30/09/2012	Preceding 3 months ended 30/06/2012	Corresponding 3 months ended 30/09/2011 in the previous year	Previous Year ended 31/03/2012
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	Number of Shares	76,41,852	76,41,739	74,08,900	76,42,476
	Percentage of Shareholding	54.85	54.84	59.54	54.84
	Promoter and Promoter Group Shareholding				
	(a) Pledged/ Encumbered				
	Number of Shares	15,77,455	12,52,455	10,52,455	10,52,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	25.07	19.90	20.90	16.72
	Percentage of shares (as a % of the total share capital of the company)	11.32	8.99	8.45	7.55
	(b) Non -encumbered				
	Number of Shares	47,14,635	50,39,748	39,82,587	55,39,011
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	74.93	80.10	79.09	83.27
	Percentage of shares (as a % of the total share capital of the company)	33.84	36.17	39.00	37.60

	Particulars	3 months ended 30/09/2012
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil



Handwritten signature/initials